Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 86 references it cites were found in a registry or an index.

DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

Open access

Abstract

Senescent vascular smooth muscle cells (VSMCs) accumulate in the vasculature with age and tissue damage and secrete factors that promote atherosclerotic plaque vulnerability and disease. Here, we report increased levels and activity of dipeptidyl peptidase 4 (DPP4), a serine protease, in senescent VSMCs. Analysis of the conditioned media from senescent VSMCs revealed a unique senescence-associated secretory phenotype (SASP) signature comprising many complement and coagulation factors; silencing or inhibiting DPP4 reduced these factors and increased cell death. Serum samples from persons with high risk for cardiovascular disease contained high levels of DPP4-regulated complement and coagulation factors. Importantly, DPP4 inhibition reduced senescent cell burden and coagulation and improved plaque stability, while single-cell resolution of senescent VSMCs reflected the senomorphic and senolytic effects of DPP4 inhibition in murine atherosclerosis. We propose that DPP4-regulated factors could be exploited therapeutically to reduce senescent cell function, reverse senohemostasis, and improve vascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci165933

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DPP4 is elevated and more active in senescent hVSMCs and mouse, monkey, and human atherosclerosis. (A) Schematic highlighting DPP4 function at the intersection of the senescence and atherosclerosis programs. (B) RT-qPCR analysis of the levels of DPP4, p21, and LMNB1 (Lamin B1) mRNAs in hVSMCs treated with DMSO, CoCl2 (200 nM), or Doxo (125 nM) for 7 days, normalized to ACTB (β-actin) mRNA levels. (C) hVSMCs were treated as in B, and the levels of proteins DPP4, p53, p21, and loading control ACTB were assessed by Western blot analysis. (D) Cell-surface proteins were biotinylated and pulled down in hVSMCs following treatment with DMSO, CoCl2, or Doxo for 7 days. Protein levels were assessed by Western blot analysis for cell-surface proteins DPP4 and VDAC1; VDAC1 input was included as a loading control. (E) DPP4 activity was measured in hVSMCs treated with DMSO, CoCl2, or Doxo for 7 days. (F) Western blot analysis of EGFR and RELA silencing in no treatment (NT) or Doxo-treated hVSMCs. (G) Ldlr–/– mice were fed ND or HFD for 16 weeks, and circulating DPP4 levels were measured in serum. (H) Aortas from 9 or 23 m.o. ApoE–/– mice were analyzed for p16 and DPP4. Original magnification, ×100. (I) Flow cytometry analysis of DPP4 on the surface of aortic VSMCs from young (n = 10) and old (n = 10) C57BL/6J mice. (J) RT-qPCR analysis of Cdkn1a, Cdkn2a, and Il1b mRNAs normalized to Actb mRNA from DPP4-positive or negative mouse VSMCs from young (n = 9, pooled 3 per data point) and old mice (n = 9, pooled 3 per data point) (Supplemental Figure 2A). (K) DPP4 in human aortic tissue (n = 5) was analyzed by IHC. Left: top row demonstrates DPP4 expression in plaque area; bottom row represents normal or nonplaque area of the same tissue. Right: analysis of the proportion of DPP4 in plaque and normal tissue in the total tissue area. Original magnification, ×10 (left panels); ×40 (right panels). (L) Immunofluorescent analysis of human atherosclerotic aortic media and neointima to colocalize DAPI (blue), DPP4 (purple), αSMA (orange), and p16 (green) signals. Original magnification, ×50 (left panels); ×100 (right panels). Data are represented as mean ± SD from n = 3 or otherwise indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Figure 1 DPP4 is elevated and more active in senescent hVSMCs and mouse, monkey, and human atherosclerosis. (A) Schematic highlighting DPP4 function at the intersection of the senescence and atherosclerosis programs. (B) RT-qPCR analysis of the levels of DPP4, p21, and LMNB1 (Lamin B1) mRNAs in hVSMCs treated with DMSO, CoCl2 (200 nM), or Doxo (125 nM) for 7 days, normalized to ACTB (β-actin) mRNA levels. (C) hVSMCs were treated as in B, and the levels of proteins DPP4, p53, p21, and loading control ACTB were assessed by Western blot analysis. (D) Cell-surface proteins were biotinylated and pulled down in hVSMCs following treatment with DMSO, CoCl2, or Doxo for 7 days. Protein levels were assessed by Western blot analysis for cell-surface proteins DPP4 and VDAC1; VDAC1 input was included as a loading control. (E) DPP4 activity was measured in hVSMCs treated with DMSO, CoCl2, or Doxo for 7 days. (F) Western blot analysis of EGFR and RELA silencing in no treatment (NT) or Doxo-treated hVSMCs. (G) Ldlr–/– mice were fed ND or HFD for 16 weeks, and circulating DPP4 levels were measured in serum. (H) Aortas from 9 or 23 m.o. ApoE–/– mice were analyzed for p16 and DPP4. Original magnification, ×100. (I) Flow cytometry analysis of DPP4 on the surface of aortic VSMCs from young (n = 10) and old (n = 10) C57BL/6J mice. (J) RT-qPCR analysis of Cdkn1a, Cdkn2a, and Il1b mRNAs normalized to Actb mRNA from DPP4-positive or negative mouse VSMCs from young (n = 9, pooled 3 per data point) and old mice (n = 9, pooled 3 per data point) (Supplemental Figure 2A). (K) DPP4 in human aortic tissue (n = 5) was analyzed by IHC. Left: top row demonstrates DPP4 expression in plaque area; bottom row represents normal or nonplaque area of the same tissue. Right: analysis of the proportion of DPP4 in plaque and normal tissue in the total tissue area. Original magnification, ×10 (left panels); ×40 (right panels). (L) Immunofluorescent analysis of human atherosclerotic aortic media and neointima to colocalize DAPI (blue), DPP4 (purple), αSMA (orange), and p16 (green) signals. Original magnification, ×50 (left panels); ×100 (right panels). Data are represented as mean ± SD from n = 3 or otherwise indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.CC BY · PubMed Central
Figure 2 Loss or inhibition of DPP4 moderately promotes death of senescent hVSMCs. (A) Micrographs depicting bright-field images of hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. Original magnification, ×20. (B) Percentage of viable cells from conditions described in A. (C) Normalized caspase-3 and -7 activity levels for cells and conditions described in A. (D–F) hVSMCs treated simultaneously with DMSO or DPP4i and DMSO, CoCl2, or Doxo for 7 days were visualized (D) and the percentage of viable cells (E), and normalized caspase-3 and -7 activity levels (F) were calculated. Original magnification, ×20. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Figure 2 Loss or inhibition of DPP4 moderately promotes death of senescent hVSMCs. (A) Micrographs depicting bright-field images of hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. Original magnification, ×20. (B) Percentage of viable cells from conditions described in A. (C) Normalized caspase-3 and -7 activity levels for cells and conditions described in A. (D–F) hVSMCs treated simultaneously with DMSO or DPP4i and DMSO, CoCl2, or Doxo for 7 days were visualized (D) and the percentage of viable cells (E), and normalized caspase-3 and -7 activity levels (F) were calculated. Original magnification, ×20. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central
Figure 3 Loss or inhibition of DPP4 reduces cell-survival proteins BCL2L1 and BCL2L2. (A) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. Graphs indicate the levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs in each group, normalized to ACTB mRNA levels. (B) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. The levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs were normalized to ACTB mRNA levels. (C) Western blot analysis of protein levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs processed as described in A. (D) Western blot analysis of the levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs treated as described in B. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Figure 3 Loss or inhibition of DPP4 reduces cell-survival proteins BCL2L1 and BCL2L2. (A) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. Graphs indicate the levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs in each group, normalized to ACTB mRNA levels. (B) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. The levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs were normalized to ACTB mRNA levels. (C) Western blot analysis of protein levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs processed as described in A. (D) Western blot analysis of the levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs treated as described in B. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.CC BY · PubMed Central
Figure 4 Senescent hVSMCS secrete procoagulation and complement factors that are suppressed by DPP4 inhibition. (A) Schematic depicting the experimental setup for mass spectrometry analysis of the media of proliferating and senescent hVSMCs treated with and without DPP4i. (B) Volcano plot of the proteins increased (red) and decreased (blue) in senescent hVSMCs compared with proliferating hVSMCs. Proteins in red and blue have a significance (–log10 adjusted P value [Padj]) ≥2. (C) Heatmap of the complement and coagulation proteins in each CoCl2 and Doxo replicate (n = 3) compared with the mean of the proliferating control for each protein. (D) Top 10 pathways enriched using BioPlanet pathway analysis ranked by combined score in senescent hVSMCs. (E) Reactome pathway analysis as ranked by combined score representative of the top elevated proteins in senescent hVSMCs. (F) STRING functional protein association network analysis to determine protein interactions among the top elevated proteins in senescent hVSMCs. (G) Volcano plot of proteins increased (red) and decreased (blue) after DPP4i treatment of senescent hVSMCs. Proteins in red and blue have a significance (–log10 Padj) ≥ 1. (H) Heatmap of complement and coagulation proteins in senescent hVSMCs (mean of CoCl2 and Doxo replicates, n = 3) compared with senescent hVSMCs treated with DPP4i (mean of CoCl2 and Doxo replicates). (I) Schematic depiction of senescence induction in hVSMCs causing increased complement and coagulation protein secretion, which is attenuated by DPP4i treatment as determined by mass spectrometry of secreted proteins in the media.
Figure 4 Senescent hVSMCS secrete procoagulation and complement factors that are suppressed by DPP4 inhibition. (A) Schematic depicting the experimental setup for mass spectrometry analysis of the media of proliferating and senescent hVSMCs treated with and without DPP4i. (B) Volcano plot of the proteins increased (red) and decreased (blue) in senescent hVSMCs compared with proliferating hVSMCs. Proteins in red and blue have a significance (–log10 adjusted P value [Padj]) ≥2. (C) Heatmap of the complement and coagulation proteins in each CoCl2 and Doxo replicate (n = 3) compared with the mean of the proliferating control for each protein. (D) Top 10 pathways enriched using BioPlanet pathway analysis ranked by combined score in senescent hVSMCs. (E) Reactome pathway analysis as ranked by combined score representative of the top elevated proteins in senescent hVSMCs. (F) STRING functional protein association network analysis to determine protein interactions among the top elevated proteins in senescent hVSMCs. (G) Volcano plot of proteins increased (red) and decreased (blue) after DPP4i treatment of senescent hVSMCs. Proteins in red and blue have a significance (–log10 Padj) ≥ 1. (H) Heatmap of complement and coagulation proteins in senescent hVSMCs (mean of CoCl2 and Doxo replicates, n = 3) compared with senescent hVSMCs treated with DPP4i (mean of CoCl2 and Doxo replicates). (I) Schematic depiction of senescence induction in hVSMCs causing increased complement and coagulation protein secretion, which is attenuated by DPP4i treatment as determined by mass spectrometry of secreted proteins in the media.CC BY · PubMed Central
Figure 5 Validation of secreted complement and coagulation proteins in senescent hVSMCs. (A) Bioplex analysis of secreted proteins from hVSMCs treated with DMSO, CoCl2, and Doxo for 7 days with (+) and without (–) DPP4i treatment. C2, C5A, C9, and FIII were measured (n = 3). (B and C) RT-qPCR analysis of mRNAs encoding complement (B) and coagulation (C) factors following treatment with DMSO (–) or DPP4i (+) as described in A. (D) Western blot analysis of the levels of factor X (FX), TIMP3, and loading control ACTB in hVSMCs that were processed as described in A. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Figure 5 Validation of secreted complement and coagulation proteins in senescent hVSMCs. (A) Bioplex analysis of secreted proteins from hVSMCs treated with DMSO, CoCl2, and Doxo for 7 days with (+) and without (–) DPP4i treatment. C2, C5A, C9, and FIII were measured (n = 3). (B and C) RT-qPCR analysis of mRNAs encoding complement (B) and coagulation (C) factors following treatment with DMSO (–) or DPP4i (+) as described in A. (D) Western blot analysis of the levels of factor X (FX), TIMP3, and loading control ACTB in hVSMCs that were processed as described in A. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.CC BY · PubMed Central
Figure 6 DPP4 downstream targets enable senescent cell viability. (A) Bioplex analysis of complement and coagulation proteins in human serum samples from people designated with low and high FRS (n = 50 per group). (B) Normalized protein intensity represented in a heatmap comparison of normal and pathological (atherosclerotic) aortic tissue from >62-year-old donors. (C) Percentage of cell viability graphed for each siRNA transfected into hVSMCs treated with Doxo (n = 2). The dashed line indicates 100% viability, and the red arrows point to siRNAs that resulted in approximately 50% reduction or increase in cell viability. (D and E) hVSMCs were treated with the indicated conditions for 7 days and micrographs were obtained (D) and caspase-3 and -7 activity levels were calculated (E). Original magnification, ×20. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Figure 6 DPP4 downstream targets enable senescent cell viability. (A) Bioplex analysis of complement and coagulation proteins in human serum samples from people designated with low and high FRS (n = 50 per group). (B) Normalized protein intensity represented in a heatmap comparison of normal and pathological (atherosclerotic) aortic tissue from >62-year-old donors. (C) Percentage of cell viability graphed for each siRNA transfected into hVSMCs treated with Doxo (n = 2). The dashed line indicates 100% viability, and the red arrows point to siRNAs that resulted in approximately 50% reduction or increase in cell viability. (D and E) hVSMCs were treated with the indicated conditions for 7 days and micrographs were obtained (D) and caspase-3 and -7 activity levels were calculated (E). Original magnification, ×20. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.CC BY · PubMed Central
Figure 7 Inhibition of DPP4 in Ldlr–/– mouse model of atherosclerosis reduces coagulation factors and senescent cell accumulation. (A) Diagram of the experimental design for treating Ldlr–/– mice with ND or HFD with vehicle or DPP4i. Following 16 weeks of diet and treatment, aortas were isolated, digested, and incubated with a DPP4 antibody–derived CITE-Seq tag for scRNA-Seq. (B) DPP4 activity levels were measured in serum from Ldlr–/– mice fed a ND (n = 4), HFD (n = 6), or HFD+DPP4i (n = 6). (C) Clotting time was measured in Ldlr–/– mice fed a ND, HFD, or HFD+DPP4i using tail bleeding as a surrogate. (D) Bioplex analysis of circulating DPP4, GDF15, and SERPINE1 in serum from Ldlr–/– mice fed a regular diet, HFD, or HFD+DPP4i. (E) Representative images (n = 4–5 per condition) of aortic roots from ND-, HFD-, and HFD+DPP4i–treated mice stained with SA–β-gal (top), Oil Red O (middle), and H&E (bottom). Original magnification, ×100. (F) Quantification of SA–β-gal–positive area. (G) Quantification of relative lesion area. (H) Quantification of necrotic core thickness based on H&E staining. (I) Quantification of cap thickness (black line) based on H&E staining. (J) Left: immunofluorescent analysis of aortic roots with DAPI (blue), FX (purple), and p21 (orange) signals. Necrotic core area indicated by NC. Right: percentage of FX, p21, or double-positive (FX+p21) cells in HFD or HFD+DPP4i mice (n = 5). Original magnification, ×40. In E, H&E HFD image is from a different crop of SF6E HFD. Significance was established using Student’s t test or 1-way ANOVA via Tukey’s HSD. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
Figure 7 Inhibition of DPP4 in Ldlr–/– mouse model of atherosclerosis reduces coagulation factors and senescent cell accumulation. (A) Diagram of the experimental design for treating Ldlr–/– mice with ND or HFD with vehicle or DPP4i. Following 16 weeks of diet and treatment, aortas were isolated, digested, and incubated with a DPP4 antibody–derived CITE-Seq tag for scRNA-Seq. (B) DPP4 activity levels were measured in serum from Ldlr–/– mice fed a ND (n = 4), HFD (n = 6), or HFD+DPP4i (n = 6). (C) Clotting time was measured in Ldlr–/– mice fed a ND, HFD, or HFD+DPP4i using tail bleeding as a surrogate. (D) Bioplex analysis of circulating DPP4, GDF15, and SERPINE1 in serum from Ldlr–/– mice fed a regular diet, HFD, or HFD+DPP4i. (E) Representative images (n = 4–5 per condition) of aortic roots from ND-, HFD-, and HFD+DPP4i–treated mice stained with SA–β-gal (top), Oil Red O (middle), and H&E (bottom). Original magnification, ×100. (F) Quantification of SA–β-gal–positive area. (G) Quantification of relative lesion area. (H) Quantification of necrotic core thickness based on H&E staining. (I) Quantification of cap thickness (black line) based on H&E staining. (J) Left: immunofluorescent analysis of aortic roots with DAPI (blue), FX (purple), and p21 (orange) signals. Necrotic core area indicated by NC. Right: percentage of FX, p21, or double-positive (FX+p21) cells in HFD or HFD+DPP4i mice (n = 5). Original magnification, ×40. In E, H&E HFD image is from a different crop of SF6E HFD. Significance was established using Student’s t test or 1-way ANOVA via Tukey’s HSD. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.CC BY · PubMed Central
Figure 8 DPP4 CITE-Seq analysis of Ldlr-/- mouse model of atherosclerosis treated with DPP4i. (A) Uniform Manifold Approximation and Projection (UMAP) plot of 16,050 aortic cells from all the samples color labeled by major cell types. (B) Dpp4 mRNA distribution across all aortic cell types. (C) DPP4 cell-surface protein expression across all aortic cell types. (D) DPP4 protein expression levels in mice fed an ND, HFD, or HFD+DPP4i (n = 4, each condition). (E) Reactome pathway analysis of transcripts with positive correlation (R >0.2) to all aortic cells with DPP4 cell-surface protein. (F) UMAP of VSMC subset reclustered in ND, HFD, and HFD+DPP4i. (G) Composition (%) of VSMC subclusters in ND, HFD, and HFD+DPP4i. (H) Heatmap of DPP4 protein (far left) and mRNAs enriched in VSMC subclusters 0 through 5. (I) Heatmap of key cluster 4 mRNAs differentially expressed in ND, HFD, and HFD+DPP4i, categorized by p53 pathway-, apoptosis-, coagulation-, and complement-related genes. ****P ≤ 0.0001.
Figure 8 DPP4 CITE-Seq analysis of Ldlr-/- mouse model of atherosclerosis treated with DPP4i. (A) Uniform Manifold Approximation and Projection (UMAP) plot of 16,050 aortic cells from all the samples color labeled by major cell types. (B) Dpp4 mRNA distribution across all aortic cell types. (C) DPP4 cell-surface protein expression across all aortic cell types. (D) DPP4 protein expression levels in mice fed an ND, HFD, or HFD+DPP4i (n = 4, each condition). (E) Reactome pathway analysis of transcripts with positive correlation (R >0.2) to all aortic cells with DPP4 cell-surface protein. (F) UMAP of VSMC subset reclustered in ND, HFD, and HFD+DPP4i. (G) Composition (%) of VSMC subclusters in ND, HFD, and HFD+DPP4i. (H) Heatmap of DPP4 protein (far left) and mRNAs enriched in VSMC subclusters 0 through 5. (I) Heatmap of key cluster 4 mRNAs differentially expressed in ND, HFD, and HFD+DPP4i, categorized by p53 pathway-, apoptosis-, coagulation-, and complement-related genes. ****P ≤ 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 2

  1. 10.1210/jcem.86.2.7219 · DOI · Paper page
  2. 10.1016/j.cell.2021.04.048 · doi:10.1016/j.cell.2021.04.048 · Paper page

Cited by

See all 50

Metadata

Authors
Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Henry-Smith, C. A., Harris, S. C., Munk, R., Martindale, J. L., Piao, Y., Fan, J., Mattison, J. A., De, S., Abdelmohsen, K., Maul, R. W., Tanaka, T., Moore, A. Z., DeMouth, M. E., Sidoli, S., Ferrucci, L., Liu, Y., de Cabo, R., Lakatta, E. G., & Gorospe, M.
Affiliations
  • National Institutes of Health (US)
  • Albert Einstein College of Medicine (US)
Corresponding author
Herman, Allison B.
Venue
Journal of Clinical Investigation
Published
2023-06-15
Volume
133
Issue
12
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4366983099
Cited by
50
References
86
Citations by year
2026: 20 · 2025: 15 · 2024: 8 · 2023: 7
FWCI
8.88
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (1s10od030286-01)
  • National Institute on Aging
  • National Cancer Institute (P30CA013330)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords
dipeptidyl peptidase IV, DPP-4 inhibition, vascular smooth muscle cell senescence, senescence-associated secretory phenotype, atherosclerotic plaque stability, complement proteins, coagulation factors, senolytic therapy, cardiovascular risk
MeSH terms
Animals, Muscle, Smooth, Vascular, Cellular Senescence, Dipeptidyl Peptidase 4, Atherosclerosis, Mice, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice. https://app.cochat.ai/papers/10.1172/jci165933
The paper
Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Henry-Smith, C. A., Harris, S. C., Munk, R., Martindale, J. L., Piao, Y., Fan, J., Mattison, J. A., De, S., Abdelmohsen, K., Maul, R. W., . . . Gorospe, M. (2023). DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci165933

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.